Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study
S Bhattacharya, AS Rathore - Journal of Chromatography B, 2023 - Elsevier
The antiangiogenic drug bevacizumab is a blockbuster therapeutic pharmaceutical product
that is used to treat many different types of cancer including kidney, colon, rectum, lung, and …
that is used to treat many different types of cancer including kidney, colon, rectum, lung, and …
Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis
J Ma, J Cai, H Chen, Z Feng, G Yang - Journal of Atherosclerosis and …, 2024 - jstage.jst.go.jp
Aim: Evidence regarding the association between various tumor necrosis factor-α (TNF-α)
inhibitors and cardiovascular adverse events (AEs) is both limited and contradictory …
inhibitors and cardiovascular adverse events (AEs) is both limited and contradictory …
Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation
Microencapsulation of the therapeutical monoclonal antibody infliximab (INF) was
investigated as an innovative approach to improve its stability and to achieve formulations …
investigated as an innovative approach to improve its stability and to achieve formulations …
炎症性肠病患者应用抗TNF-α 单抗发生结核风险的研究进展.
苏建淋， 廖盛涛， 李传飞， 吕琳 - Journal of Modern Medicine …, 2024 - search.ebscohost.com
炎症性肠病(IBD) 是一种胃肠道慢性非特异性复发性炎症性疾病. 抗肿瘤坏死因子-α (TNF-α)
单抗的出现极大地改善了IBD 患者的预后, 但同时也增加了患者发生活动性结核的风险 …
单抗的出现极大地改善了IBD 患者的预后, 但同时也增加了患者发生活动性结核的风险 …
Biologics In Vitro Characterization Advancements to Streamline Development and Approval Timelines
J Kinzer - 2023 - deepblue.lib.umich.edu
Monoclonal antibodies (mAbs) account for 120+ FDA approved products and are frequently
used to treat patients with chronic autoimmune diseases or cancer. Despite being approved …
used to treat patients with chronic autoimmune diseases or cancer. Despite being approved …